140 related articles for article (PubMed ID: 1824264)
1. Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice.
Porter JB; Hoyes KP; Abeysinghe RD; Brooks PN; Huehns ER; Hider RC
Blood; 1991 Nov; 78(10):2727-34. PubMed ID: 1824264
[TBL] [Abstract][Full Text] [Related]
2. Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice.
Porter JB; Morgan J; Hoyes KP; Burke LC; Huehns ER; Hider RC
Blood; 1990 Dec; 76(11):2389-96. PubMed ID: 2257308
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.
Hoyes KP; Jones HM; Abeysinghe RD; Hider RC; Porter JB
Exp Hematol; 1993 Jan; 21(1):86-92. PubMed ID: 8417963
[TBL] [Abstract][Full Text] [Related]
4. Protoporphyria induced by the orally active iron chelator 1,2-diethyl-3-hydroxypyridin-4-one in C57BL/10ScSn mice.
Smith AG; Clothier B; Francis JE; Gibbs AH; De Matteis F; Hider RC
Blood; 1997 Feb; 89(3):1045-51. PubMed ID: 9028337
[TBL] [Abstract][Full Text] [Related]
5. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts.
Selig RA; White L; Gramacho C; Sterling-Levis K; Fraser IW; Naidoo D
Cancer Res; 1998 Feb; 58(3):473-8. PubMed ID: 9458092
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.
Chenoufi N; Hubert N; Loréal O; Morel I; Pasdeloup N; Cillard J; Brissot P; Lescoat G
J Hepatol; 1995 Aug; 23(2):166-73. PubMed ID: 7499788
[TBL] [Abstract][Full Text] [Related]
7. Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating site.
Porter JB; Abeysinghe RD; Hoyes KP; Barra C; Huehns ER; Brooks PN; Blackwell MP; Araneta M; Brittenham G; Singh S
Br J Haematol; 1993 Sep; 85(1):159-68. PubMed ID: 8251385
[TBL] [Abstract][Full Text] [Related]
8. Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig.
Wong A; Alder V; Robertson D; Papadimitriou J; Maserei J; Berdoukas V; Kontoghiorghes G; Taylor E; Baker E
Biometals; 1997 Oct; 10(4):247-56. PubMed ID: 9353871
[TBL] [Abstract][Full Text] [Related]
9. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.
Hamilton JL; Imran Ul-Haq M; Abbina S; Kalathottukaren MT; Lai BF; Hatef A; Unniappan S; Kizhakkedathu JN
Biomaterials; 2016 Sep; 102():58-71. PubMed ID: 27322959
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
Morel I; Cillard J; Lescoat G; Sergent O; Pasdeloup N; Ocaktan AZ; Abdallah MA; Brissot P; Cillard P
Free Radic Biol Med; 1992 Nov; 13(5):499-508. PubMed ID: 1334028
[TBL] [Abstract][Full Text] [Related]
11. Iron chelators as therapeutic agents against Pneumocystis carinii.
Weinberg GA
Antimicrob Agents Chemother; 1994 May; 38(5):997-1003. PubMed ID: 8067783
[TBL] [Abstract][Full Text] [Related]
12. Selection of hydroxypyridin-4-ones for the treatment of iron overload using in vitro and in vivo models.
Huehns ER; Porter JB; Hider RC
Hemoglobin; 1988; 12(5-6):593-600. PubMed ID: 3209401
[TBL] [Abstract][Full Text] [Related]
13. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant.
Porter JB; Gyparaki M; Burke LC; Huehns ER; Sarpong P; Saez V; Hider RC
Blood; 1988 Nov; 72(5):1497-503. PubMed ID: 3179437
[TBL] [Abstract][Full Text] [Related]
14. Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes.
Maclean KH; Cleveland JL; Porter JB
Blood; 2001 Dec; 98(13):3831-9. PubMed ID: 11739193
[TBL] [Abstract][Full Text] [Related]
15. Novel orally active iron chelators (3-hydroxypyridin-4-ones) enhance the biliary excretion of plasma non-transferrin-bound iron in rats.
Zanninelli G; Choudury R; Loréal O; Guyader D; Lescoat G; Arnaud J; Verna R; Cosson B; Singh S; Hider RC; Brissot P
J Hepatol; 1997 Jul; 27(1):176-84. PubMed ID: 9252093
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of hydroxypyridone iron chelators in a mouse model.
Gyparaki M; Porter JB; Hirani S; Streater M; Hider RC; Huehns ER
Acta Haematol; 1987; 78(2-3):217-21. PubMed ID: 3120475
[TBL] [Abstract][Full Text] [Related]
17. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.
Hoyes KP; Porter JB
Br J Haematol; 1993 Oct; 85(2):393-400. PubMed ID: 8280612
[TBL] [Abstract][Full Text] [Related]
18. Effect of iron overload on the metabolism and urinary recovery of 3-hydroxypyridin-4-one chelating agents in the rat.
Choudhury R; Singh S
Drug Metab Dispos; 1995 Mar; 23(3):314-20. PubMed ID: 7628295
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
Kontoghiorghes GJ
Toxicol Lett; 1995 Oct; 80(1-3):1-18. PubMed ID: 7482575
[TBL] [Abstract][Full Text] [Related]
20. The effect of N-alkyl modification on the antimalarial activity of 3-hydroxypyridin-4-one oral iron chelators.
Hershko C; Theanacho EN; Spira DT; Peter HH; Dobbin P; Hider RC
Blood; 1991 Feb; 77(3):637-43. PubMed ID: 1991172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
